Merck and Moderna's mRNA vaccine became the first neoantigen cancer therapy to clear Phase 3 trials, outperforming Keytruda alone at preventing melanoma's return in 1,000+ patients.
FDA approval is next step.

Merck and Moderna's mRNA vaccine became the first neoantigen cancer therapy to clear Phase 3 trials, outperforming Keytruda alone at preventing melanoma's return in 1,000+ patients.
FDA approval is next step.